Wexford Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wexford Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,900	Closed	-$354K	–	153
2017 Q2	$354K	Buy	+3,900	New	+$355K	0.03%	133
2014 Q4	–	Sell	-5,000	Closed	-$361K	–	63
2014 Q3	$361K	Sell	5,000 -48,299	-91%	-$3.17M	0.03%	103
2014 Q2	$3.32M	Buy	+53,299	New	+$3.22M	0.25%	48

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's BMRN Position: Q3 2017 in Review

Wexford Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 3,900 shares — an estimated $354K sold.

Wexford Capital first reported a position in BMRN in Q2 2014 and held it in 3 quarters. The position peaked at $3.32M in Q2 2014. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Wexford Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Wexford Capital sold 3,900 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $354K.
Wexford Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Wexford Capital's BioMarin Pharmaceuticals position peaked at $3.32M in Q2 2014.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.